Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients

The recruitment status of this study is unknown because the information has not been verified recently.

Verified April 2006 by University Hospital Muenster. Recruitment status was Recruiting

First Received on August 18, 2005. Last Updated on April 11, 2006 History of Changes

Sponsor:	University Hospital Muenster
Information provided by:	University Hospital Muenster
ClinicalTrials.gov Identifier:	NCT00132223

Purpose

Angiographies of the supra-aortic vessels by magnetic imaging have become common recently. So it was the purpose of this study to evaluate the imaging potential of different contrast agents.

Three contrast agents for magnetic resonance imaging are compared in angiographies of the supra-aortic arteries in a intraindividual study of 10 patients.

All applications of these contrast agents are performed with a flow of 2 ml/s. One contrast medium is applicated a second time with a reduced flow of 1 ml/s.

The angiographies of the supra-aortic vessels are evaluated by two experienced readers in a consensus reading. The signal/noise- and contrast/noise-ratio of anatomic vessel segments of the carotic and vertebral arteries are measured and compared to each other.

Condition	Intervention	Phase
Headache Epilepsy Dizziness	Drug: Contrast agent	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Single Blind Primary Purpose: Diagnostic
Official Title:	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging

Resource links provided by NLM:

Genetics Home Reference related topics: Ménière disease pyridoxal 5'-phosphate-dependent epilepsy

MedlinePlus related topics: Dizziness and Vertigo Epilepsy Headache Noise

U.S. FDA Resources

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:

intensity of vessels, muscle, air

Secondary Outcome Measures:

signal/noise ratio
contrast/nose ratio

Estimated Enrollment:	10
Study Start Date:	April 2005
Estimated Study Completion Date:	December 2005

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Headache
Epilepsia
Dizziness

Exclusion Criteria:

Pregnancy
Metal implants (e.g. pacemaker)
Contraindication for contrast agent
Multiple allergies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00132223

Contacts

Contact: Boris Buerke, MD	00492518345123	buerkeb@uni-muenster.de
Contact: Bernd Tombach, MD	00492518345123	tombach@uni-muenster.de

Locations

Germany
University of Muenster, Dept. of Clinical Radiology	Recruiting
Muenster, Germany, 48129
Contact: Boris Buerke, MD 00492518345123 buerkeb@uni-muenster.de
Contact: Bernd Tombach 00492518345123 tombach@uni-muenster.de
Principal Investigator: Bernd Tombach, MD
Sub-Investigator: Boris Buerke, MD

Sponsors and Collaborators

University Hospital Muenster

Investigators

Study Chair:

Bernd Tombach, MD

University of Muenster, Dept. of Clinical Radiology

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00132223 History of Changes
Other Study ID Numbers:	0710/2004-IKR
Study First Received:	August 18, 2005
Last Updated:	April 11, 2006
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University Hospital Muenster:

magnetic imaging
angiography
contrast agent

signal/noise ratio
contrast/noise ratio
vessel

Additional relevant MeSH terms:

Dizziness
Vertigo
Epilepsy
Headache
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

Vestibular Diseases
Labyrinth Diseases
Ear Diseases
Otorhinolaryngologic Diseases
Brain Diseases
Central Nervous System Diseases
Pain

ClinicalTrials.gov processed this record on February 13, 2012